The FDA should strengthen the evidence required for the approval of drugs under its accelerated pathway and increase the ...
Greater transparency in FDA decision-making was possibly the most common theme for stakeholders interviewed by the Institute ...
By Sneha S K April 16 (Reuters) - The U.S. Food and Drug Administration should be more transparent when granting accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results